FDA rejects emergency use authorisation for Covaxin in a setback for India-made jab


Hyderabad: In a setback to Bharat Biotech’s COVID-19 vaccine Covaxin, the US Food and Drug Administration has “recommended” Ocugen Inc, the US companion of the Indian vaccine maker, to go for Biologics Licence Application (BLA) route with extra information, nixinghopes of Emergency Use Authorisation.

Ocugen in a press release on Thursday introduced that as really useful by the FDA, it is going to pursue submission of a biologics licence utility (BLA) for Covaxin. BLA, is a “full approval” mechanism by the FDA for medication and vaccines.

“The company will no longer pursue an Emergency Use Authorization (EUA) for Covaxin. The FDA provided feedback to Ocugen regarding the Master File. The company had previously submitted and recommended that Ocugen pursue a BLA submission instead of an EUA application for its vaccine candidate and requested additional information and data,” Ocugen mentioned.

The growth could delay the Covaxin launch within the US, Ocugen mentioned. Ocugen is in discussions with the FDA to grasp the extra info required to assist a BLA submission.
The firm anticipates that information from a further medical trial can be required to assist the submission.

“Although we were close to finalising our EUA application for submission, we received a recommendation from the FDA to pursue a BLA path. While this will extend our timelines, we are committed to bringing Covaxin to the US,” Dr. Shankar Musunuri, Chairman of the Board, Chief Executive Officer and co-founder of Ocugen mentioned.

“This differentiated vaccine is a essential device to incorporate in our nationwide arsenal given its potential to address the SARS-CoV-2 variants, together with the delta variant, and given the unknowns about what can be wanted to guard US inhabitants in the long run,” he added.

Ocugen just lately introduced that it secured unique rights to commercialise Covaxin in Canada and has initiated discussions with Health Canada for regulatory approval.
The firm will pursue expedited authorisation for the vaccine beneath the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 in Canada.

Live TV

Source link